Industry
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Biofarma Group's R&D to support people in the pre-depressive phase.
Ensemble No.3 (ENS-003) is in development to address vulvovaginal candidiasis – a vaginal yeast infection for which antifungal treatments offer limited protection from recurrence.
A large Korean population study provides scientific evidence that altering the gut microbiome composition through dietary habit change can help prevent and manage the hypertension.
Industry
Sponsored by
The 6’-SL HMO from Chr. Hansen is approved for highest use levels in infant formula and follow-on formula in EU.
Industry
Sponsored by
The French family company has acquired 100% of TargEDys’ shares, to consolidate the group’s strong ambition in the Microbiome and accelerate TargEDys’ development globally.
Industry
Sponsored by
Tensred plus®: an innovative formula to combat pre-hypertension.
Key outputs and innovations of direct relevance to food and agriculture from the H2020 funded MASTER project.
